Form 4: Amphastar Director Schedules Future Stock Sales

Amphastar Pharmaceuticals Director Floyd F. Petersen reported scheduled sales of 4,163 shares of common stock under a Rule 10b5-1 plan.

Summary

• Floyd F. Petersen, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), filed a Form 4 reporting scheduled future transactions.
• The filing indicates the sale of 1,737 shares of Common Stock on December 11, 2025, at a price of $25.688 per share.
• An additional 2,426 shares of Common Stock are scheduled to be sold on December 12, 2025, at a weighted average price of $25.9226 per share, with prices ranging from $25.9225 to $25.945.
• These transactions are being conducted pursuant to a Rule 10b5-1 trading plan, which was established to satisfy affirmative defense conditions.
• Following these scheduled sales, Mr. Petersen's direct beneficial ownership will be 71,368 shares of Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can be perceived negatively, the fact that these are pre-scheduled sales under a Rule 10b5-1 plan mitigates immediate concerns, suggesting a planned financial event rather than a reaction to new adverse information.

Positives

• The sales are being conducted under a Rule 10b5-1 trading plan, indicating they are pre-scheduled and not based on immediate, material non-public information, which can mitigate negative market perception.
• The filing provides transparency by pre-reporting these future transactions.

Negatives

• A director's decision to reduce their stake, even if pre-planned, can sometimes be interpreted by investors as a signal of limited future upside or a desire to diversify away from the company's stock.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on the insider's scheduled stock transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price for the December 12, 2025 transaction.

Industry Context

This filing is specific to an insider transaction at Amphastar Pharmaceuticals and does not directly provide context on broader industry trends or competitor activities. Insider sales are a common occurrence across various industries, often for personal financial planning reasons.

Corporate Governance

Stakeholder Impact

• Shareholders may view the director's decision to reduce their stake with caution, although the pre-planned nature under Rule 10b5-1 lessens the immediate negative implication.

Next Steps

• The reporting person has undertaken to provide additional details on the weighted average price transactions upon request.

Key Dates

Recommendation

The scheduled sale of shares by a director, while a notable event, is being conducted under a Rule 10b5-1 plan. This indicates the transactions are pre-arranged and not necessarily driven by new, material non-public information. Investors should monitor broader company performance and future insider activity rather than making a definitive investment decision based solely on this pre-reported, planned transaction.

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Director Share Sale, Floyd F. Petersen, Common Stock, Rule 10b5-1 Plan